|
FDA panel backs approval of GSK's mepolizumab for severe asthma
ModernMedicine FDA's Pulmonary-Allergy Drugs Advisory Committee recently recommended approval of GlaxoSmithKline Plc's drug mepolizumab (Nucala) for severe asthma in patients aged 18 years and older. However, the panel voted 10 to 4 against approving the drug in … |
View full post on asthma – Google News